201 results
424B3
MBRX
Moleculin Biotech Inc
16 Feb 24
Prospectus supplement
5:19pm
regulations.
We are exposed to the risk of employee fraud or other illegal activity by our employees, independent contractors, consultants … continued listing requirements and standards, including those regarding director independence and independent committee requirements, minimum stockholders
8-K
EX-99.1
2h4ui96
24 Jan 24
Regulation FD Disclosure
8:50am
424B5
0sbuxtjoakovb1
22 Dec 23
Prospectus supplement for primary offering
5:00pm
8-K
EX-4.1
poo8sfqwt10rd n8
21 Dec 23
Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
5:17pm
8-K
EX-10.1
eeiw8q felkwy
21 Dec 23
Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
5:17pm
8-K
EX-10.2
edb7t5nk2
21 Dec 23
Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
5:17pm
8-K
EX-4.2
98kvuzbn
21 Dec 23
Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
5:17pm
8-K
EX-99.1
lsg 7wttztm2nqgat
13 Nov 23
Regulation FD Disclosure
8:05am
8-K
EX-99.1
ph1tey ra5ve
13 Nov 23
Moleculin Reports Third Quarter 2023 Financial Results
8:00am
8-K
EX-99.1
cm7d07gr 8u
18 Sep 23
Moleculin Announces New Positive Independent Report of No Cardiotoxicity in Annamycin
8:40am
8-K
fi6zbwf3uk4
18 Sep 23
Moleculin Announces New Positive Independent Report of No Cardiotoxicity in Annamycin
8:40am
8-K
EX-99.1
p1asisx
10 Aug 23
Moleculin Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones
4:05pm